Rein Therapeutics Inc (RNTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $34.51M
Last updated: Nov 17, 2026 at 4:29 PM ET
Rein Therapeutics Inc (RNTX) Stock Chart
Rein Therapeutics (RNTX) has a latest price of $0.36 on Nov 17, 2026, 83.0% below its 52-week high of $2.10. Its price fell 71.5% over the past 12 months. The month-end price fell 70.1% over the 10 years through Oct 2026, a compound annual decline of 11.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $267.60 in Sep 2017 and its lowest $0.67 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RNTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RNTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 55.0%, and over 6 months it fell 64.2%. The month-end price fell 42.7% over the 3 years through Oct 2026, a compound annual decline of 17.0%.
| Period | Change |
|---|---|
| 1 month | -35.4% |
| 3 months | -55.0% |
| 6 months | -64.2% |
| 12 months | -71.5% |
| 12 months, with dividends | -71.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -42.7% | -17.0% |
| 5 years | -96.1% | -47.9% |
| 10 years | -70.1% | -11.4% |
Price by Year
Its best calendar year was 2017, when the price rose 9,302.3%, and its weakest was 2018, when it fell 92.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.67 | -42.2% |
| 2025 | $1.16 | -49.6% |
| 2024 | $2.30 | -24.6% |
| 2023 | $3.05 | +28.6% |
| 2022 | $2.37 | -78.9% |
| 2021 | $11.26 | -45.9% |
| 2020 | $20.80 | +81.5% |
| 2019 | $11.46 | -31.8% |
| 2018 | $16.80 | -92.0% |
| 2017 | $210.80 | +9,302.3% |
Trading Range
The price is 48.5% below its 50-day average of $0.69 and 64.1% below its 200-day average of $0.99.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.36 | |
| 52-week high | $2.10 | -83.0% |
| 52-week low | $0.28 | +25.5% |
| 50-day average | $0.69 | -48.5% |
| 200-day average | $0.99 | -64.1% |
Price Risk
Over 3 years, its largest fall from a peak was 94.9%.
| Measure | Value |
|---|---|
| 1-year beta | 2.38 |
| Largest fall, 1 year | -81.0% |
| Largest fall, 3 years | -94.9% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RNTX
What is RNTX's 1-year price change?
Rein Therapeutics's price fell 71.5% over the past 12 months. With dividends included, the 12-month total return was -71.5%.
What is RNTX's 5-year price change?
Rein Therapeutics's month-end price fell 96.1% over the 5 years through Oct 2026, a compound annual decline of 47.9%. These figures leave out dividends.
What is RNTX's 52-week high and low?
Rein Therapeutics's 52-week high is $2.10 and its 52-week low is $0.28. Its latest price of $0.36 on Nov 17, 2026 is 83.0% below the high.
What is RNTX's beta?
Rein Therapeutics's 1-year beta against the S&P 500 is 2.38, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 81.0%.
Is the RNTX chart free?
Yes. Advanced Charting for RNTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RNTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors